Background: Dementia is characterized by a chronic and progressive loss of cognitive function in the absence of a fluctuating level of consciousness. Alzheimer's disease is the main etiology of dementia, presenting insidiously and causing progressive cognitive impairment with increasing severity over the years. Given the immense complexity of managing patients with advanced dementia, the Advanced Cognitive Impairment Outpatient Clinic (ACIOC) of the Geriatric Service of the Internal Medicine Division of the Hospital das Clínicas of the Faculty of Medicine of the University of São Paulo (HCFMUSP) was created in April 2008, which aimes to monitor elderly patients referred from other outpatient clinics, with moderate to advanced dementia, for multidisciplinary follow-up: doctor, speech therapist, occupational therapist and dentist. Given the complexity of patients with advanced dementia, each patient is assessed, in person, on average, 4 times a year.
Method: To describe the functioning and sample of patients that make up the ACIOC, according to data collected via electronic medical records between August 2018 and January 2024.
Result: Electronic medical records were implemented in August 2018. Data taken from records indicate that 246 patients were assisted between August 2018 and January 2024, with an average age of 79.10 years. The majority of patients were white (60%), female (65%) and had 5 years of schooling, on average. The main comorbidities were: hypertension (40%), coronary artery disease (40%) and diabetes mellitus (17%). Regarding the etiology of dementia, Alzheimer's was the most prevalent (28%), followed by Vascular (15%), Mixed (12%), Frontotemporal (5%), LBD (4,8%) and 23% of patients did not have diagnosis. Regarding the treatment carried out, 61% were treated with anticholinesterases, 59% with antidepressants, 53% with antipsychotics and 46% with memantine.
Conclusion: The data obtained highlights the importance of ACIOC in dementia care, especially for those residing in São Paulo / Brazil. This study seeks not only to contribute to the understanding of dementia in the Brazilian context, but also emphasizes the need to share these findings to improve services offered in other institutions dedicated to the care of these patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.093218 | DOI Listing |
BMC Geriatr
January 2025
International Observatory on End of Life Care, Lancaster University, Lancaster, UK.
Background: Namaste Care is an intervention designed to improve the quality of life for people with advanced dementia by providing individualised stimulation and personalised activities in a group setting. Current evidence indicates there may be benefits from this intervention, but there is a need to explore the practical realities of its implementation, including potential barriers, enablers, and how it is delivered within the context of nursing care homes.
Objective: To systematically assess the factors involved in implementing Namaste Care for people with advanced dementia in nursing care homes.
Anesthesiology
January 2025
Department of Neuroradiology, School of Medicine and Health, Technical University of Munich, Germany.
Background: According to the model of the glymphatic system, the directed flow of cerebrospinal fluid (CSF) is a driver of waste clearance from the brain. In sleep, glymphatic transport is enhanced, but it is unclear how it is affected by anesthesia. Animal research indicates partially opposing effects of distinct anesthetics but corresponding results in humans are lacking.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Joseph Sagol Neuroscience Center, Sheba Medical Center, Tel Hashomer, Israel.
Background: Amyloid beta (Aβ) deposition marks an early stage in the progression of Alzheimer's disease (AD), detectable in-vivo years before symptoms emerge and targeted by recently FDA-approved drugs. This has propelled advancements in understanding, measuring, and treating AD, paving the way for disease prevention in those at risk. However, the psychological impact of disclosing Aβ status to cognitively unimpaired individuals remains underexplored.
View Article and Find Full Text PDFBackground: The Amyloid-Tau-Neurodegeneration (ATN) biomarker framework for Alzheimer's disease (AD) indicates binary (presence/absence) designations for each type of pathology, without regard for anatomical distribution. Neurodegeneration is designated as positive if atrophy or hypometabolism are found on imaging. However, Clifford Jack et al.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Clinical Neurochemistry Laboratory Sahlgrenska University Hospital, Mölndal, Sweden.
Background: This research introduces a novel method for quantifying aggregated tau in body fluids, specifically cerebrospinal fluid (CSF), aiming to enhance the diagnosis and monitoring of neurodegenerative diseases, with a focus on Alzheimer's disease (AD).
Method: By combining tau protein amplification with a highly sensitive single-molecule array (Simoa) immunoassay using an anti-tau antibody CT19.1 in a homogenous manner, the approach enables precise measurements of tau aggregates in CSF.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!